Luis Paz-Ares

Luis Paz-Ares publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Luis Paz-Ares sits on this spectrum.

Luis Paz-Ares D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Luis Paz-Ares sits on this spectrum.

Overview

Best Publications

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  4828
  Citations

• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  Rafael Rosell;Teresa Moran;Cristina Queralt;Rut Porta

  2916
  Citations

• Lung cancer: current therapies and new targeted treatments

  Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon

  2845
  Citations

• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

  Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  2247
  Citations

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  1754
  Citations

• International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

  GM Mead;SP Stenning;P Cook;SD Fossa

  1632
  Citations

• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

  Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  1372
  Citations

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  1269
  Citations

• First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

  Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu

  1153
  Citations

• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

  Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  1039
  Citations

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  946
  Citations

• Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

  Luis Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  804
  Citations

• Current Challenges in Cancer Treatment.

  Jon Zugazagoitia;Cristiano Guedes;Santiago Ponce;Irene Ferrer

  786
  Citations

• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

  Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski

  778
  Citations

• PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

  Luis G. Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  754
  Citations

• First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

  Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  749
  Citations

• Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

  Joaquim Bellmunt;Hans von der Maase;Graham M. Mead;Iwona Skoneczna

  653
  Citations

• Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

  Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  625
  Citations

• Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

  Ricardo Hitt;Antonio López-Pousa;Javier Martínez-Trufero;Vicente Escrig

  595
  Citations

• 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

  J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  530
  Citations